Comparison of atorvastatin and rosuvastatin on preventing contrast-induced-nephropathy in patients undergoing primary percutaneous coronary intervention: A multi-centric randomized triple-blind clinical trial

Background: Patients with Contrast-Induced-Nephropathy (CIN) are at a greater risk of in-hospital complications, longer hospitalization, and long-term mortality in comparison with those without CIN. Despite many studies on the helpful effects of statins in preventing contrast-nephropathy, there is not enough evidence comparing different statins in inhibiting CIN. So, we planned this study to compare the efficacy of rosuvastatin and atorvastatin in prevention of contrast-induced nephropathy. Methods: This was a randomized clinical trial. The efficacy of two known statins, atorvastatin and rosuvastatin were compared in prevention of CIN in patients with ST-Elevation Myocardial Infarction (STEMI) who underwent Primary Percutaneous Intervention (PPCI) between May 2015 and April 2016 in Qaem and Imam Reza hospital, Mashhad, Iran. Subjects were divided randomly to 80-mg atorvastatin or 40-mg rosuvastatin group before PPCI. Participants’ characteristics including echocardiographic, laboratory and demographic data were recorded and incidence of CIN was assessed. Results: Two hundred cases with STEMI undergoing PPCI were recruited in the study and randomized to 80-mg atorvastatin (n = 98) or 40-mg rosuvastatin (n = 102) group before PPCI. The incidence of CIN was 5.67% (n = 13) in all participants; 6.3% (n = 7) in the rosuvastatin group and 5.1% (n = 6) in the atorvastatin group. There was a significant difference between creatinine and Glomerular Filtration Rate (GFR) after 48 hours of PPCI. Creatinine was lower and GFR was higher in the rosuvastatin group (P = 0.029, P = 0.005). Conclusion: There was a little trend for prevention of CIN in patients after PPCI in rosuvastatin group compared to atorvastatin group, in full dose. However, this preference was not clinically relevant.

Rosuvastatin; Atorvastatin; Primary percutaneous coronary intervention; ST elevation myocardial infarction

[1] Marenzi G, Bartorelli AL. 27 contrast-induced nephropathy in patients undergoing primary angioplasty: Prognostic implications, prevention, and management. Mechanical Reperfusion for STEMI: From Random-ized Trials to Clinical Practice. 2016.

[2] Kapoor A, Gaur P. Contrast-induced nephropathy. Coronary Angioplasty: Evolved to Perfection. Jaypee Brothers Medical Publishers (P) Ltd. 2017.

[3] McCullough PA. Contrast-induced acute kidney injury. Journal of the American College of Cardiology. 2008; 51: 1419-1428.

[4] Grossman PM, Ali SS, Aronow HD, Boros M, Nypaver TJ, Schreiber TL, et al. Contrast-induced nephropathy in patients undergoing endovascular peripheral vascular intervention: Incidence, risk factors, and outcomes as observed in the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Journal of Interventional Cardiology. 2017; 30: 274-280.

[5] Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. circulation. 2002; 105: 2259-2264.

[6] Liss P, Persson P, Hansell P, Lagerqvist B. Renal failure in 57 925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media. Kidney International. 2006; 70: 1811-1817.

[7] Freeman RV, O’Donnell M, Share D, Meengs WL, Kline-Rogers E, Clark VL, et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. The American Journal of Cardiology. 2002; 90: 1068-1073.

[8] Gurm HS, Dixon SR, Smith DE, Share D, LaLonde T, Greenbaum A, et al. Renal function-based contrast dosing to define safe limits of radiographic contrast media in patients undergoing percutaneous coronary interventions. Journal of the American College of Cardiology. 2011; 58: 907-914.

[9] Reed M, Meier P, Tamhane UU, Welch KB, Moscucci M, Gurm HS. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials. JACC: Cardiovascular Interventions. 2009; 2: 645-654.

[10] Narula A, Mehran R, Weisz G, Dangas GD, Yu J, Généreux P, et al. Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy. European Heart Journal. 2014; 35: 1533-1540.

[11] Senoo T, Motohiro M, Kamihata H, Yamamoto S, Isono T, Manabe K, et al. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome. The American Journal of Cardiology. 2010; 105: 624-628.

[12] Verdoodt A, Honore PM, Jacobs R, De Waele E, Van Gorp V, De Regt J, et al. Do Statins Induce or Protect from Acute Kidney Injury and Chronic Kidney Disease: An Update Review in 2018. Journal of Translational Internal Medicine. 2018; 6: 21-25.

[13] Esmeijer K, Dekkers OM, de Fijter JW, Dekker FW, Hoogeveen EK. Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis. Scientific Reports. 2019; 9: 1-13.

[14] Farmer JA. Pleiotropic effects of statins. Current Atherosclerosis Reports. 2000; 2: 208-217.

[15] Wang N, Qian P, Yan TD, Phan K. Periprocedural effects of statins on the incidence of contrast-induced acute kidney injury: A systematic review and trial sequential analysis. International Journal of Cardiology. 2016; 206: 143-152.

[16] Thompson K, Razi R, Lee MS, Shen A, Stone GW, Hiremath S, et al. Statin use prior to angiography for the prevention of contrast-induced acute kidney injury: a meta-analysis of 19 randomised trials. EuroIntervention. 2016; 12: 366-374.

[17] Chyou AC, Thodge A, Feldman DN, Swaminathan RV. Statins in the prevention of contrast-induced nephropathy. Current Treatment Options in Cardiovascular Medicine. 2015; 17: 15.

[18] Kaya A, Kurt M, Tanboga IH, Işik T, Ekinci M, Aksakal E, et al. Ros uvastatin versus A torvastatin to prevent C ontrast I nduced N ephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-CIN trial). Acta Cardiologica. 2013; 68: 489-494.

[19] Liu Y, Liu Y-h, Tan N, Chen J-y, Zhou Y-l, Li L-w, et al. Comparison of the efficacy of rosuvastatin versus atorvastatin in preventing contrast induced nephropathy in patient with chronic kidney disease undergoing percutaneous coronary intervention. PLoS One. 2014; 9: e111124.

[20] Harjai KJ, Raizada A, Shenoy C, Sattur S, Orshaw P, Yaeger K, et al. A comparison of contemporary definitions of contrast nephropathy in patients undergoing percutaneous coronary intervention and a proposal for a novel nephropathy grading system. The American Journal of Cardiology. 2008; 101: 812-819.

[21] Rear R, Bell RM, Hausenloy DJ. Contrast-induced nephropathy following angiography and cardiac interventions. Heart. 2016; 102: 638-648.

[22] Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. Journal of the American Society of Nephrology. 2000; 11: 177-182.

[23] Park SH, Jeong MH, Park IH, Choi JS, Rhee JA, Kim IS, et al. Effects of combination therapy of statin and N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary inter-vention. International Journal of Cardiology. 2016; 212: 100-106.

[24] Kandula P, Shah R, Singh N, Markwell SJ, Bhensdadia N, Navaneethan SD. Statins for prevention of contrast-induced nephropathy in patients un-dergoing non-emergent percutaneous coronary intervention. Nephrology. 2010; 15: 165-170.

[25] Toso A, Maioli M, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, et al. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. The American Journal of Cardiology. 2010; 105: 288-292.

[26] Quintavalle C, Fiore D, De Micco F, Visconti G, Focaccio A, Golia B, et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation. 2012; 112: 103317.

[27] Hoshi T, Sato A, Kakefuda Y, Harunari T, Watabe H, Ojima E, et al. Preventive effect of statin pretreatment on contrast-induced acute kidney injury in patients undergoing coronary angioplasty: propensity score analysis from a multicenter registry. International Journal of Cardiology. 2014; 171: 243-249.

[28] Li W, Fu X, Wang Y, Li X, Yang Z, Wang X, et al. Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention. Cardiology. 2012; 122: 195-202.

[29] Patti G, Cannon CP, Murphy SA, Mega S, Pasceri V, Briguori C, et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary interventionclinical perspective. Circulation. 2011; 123: 1622-1632.

[30] Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). Journal of the American College of Cardiology. 2014; 63: 71-79.

[31] Han Y, Zhu G, Han L, Hou F, Huang W, Liu H, et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. Journal of the American College of Cardiology. 2014; 63: 62-70.

[32] Toth PP. An update on the benefits and risks of rosuvastatin therapy. Postgraduate Medicine. 2014; 126: 7-17.

[33] Betteridge DJ, Gibson JM, Sager PT. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (< 2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dL) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). The American Journal of Cardiology. 2007; 100: 1245-1248.

[34] Ridker PM, MacFadyen J, Cressman M, Glynn RJ. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention–an Intervention Trial Evaluating Rosuvastatin) trial. Journal of the American College of Cardiology. 2010; 55: 1266-1273.

[35] Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. Journal of Internal Medicine. 2004; 255: 188-205.

[36] Wong PCY, Li Z, Guo J, Zhang A. Pathophysiology of contrast-induced nephropathy. International Journal of Cardiology. 2012; 158: 186-192.

[37] Andò G, Morabito G, Gregorio C, Trio O, Saporito F, Oreto G. Age, glomerular filtration rate, ejection fraction, and the AGEF score predict contrast-induced nephropathy in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Catheterization and Cardiovascular Interventions. 2013; 82: 878-885.